您现在的位置是:8 k y 1 m 4 w 4 c q g i 8 6 2 j s f 3 n 5 8 0 u a u > Fashion
【performance goals and expectations ncoer】Evotec to Attend Upcoming Investor Conferences
8 k y 1 m 4 w 4 c q g i 8 6 2 j s f 3 n 5 8 0 u a u2024-09-29 12:18:30【Fashion】0人已围观
简介HAMBURG, GERMANY / ACCESSWIRE / November 4, 2020 /Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/Tec performance goals and expectations ncoer
HAMBURG,performance goals and expectations ncoer GERMANY / ACCESSWIRE / November 4, 2020 /
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that its management will be presenting at and attending the following upcoming conferences until the end of 2020:
Consilium Strategic Communications 8
th
Annual Healthcare Conference
Date
:
Monday, 16 November 2020
Venue
:
Virtual
Attendee
:
Enno Spillner, Chief Financial Officer
German Equity Forum
Date
:
Monday, 16 November 2020
,
Presentation: 16 November 2020, 2.00 pm (CET)
Venue
:
Virtual
Attendee
:
Dr Werner Lanthaler, Chief Executive Officer
Jefferies London Healthcare Conference
Date
:
Tuesday, 17 November 2020
and Thursday, 19 November 2020
,
Presentation: 19 November 2020, 8.20 am (CET)
Venue
:
Virtual
Attendee
:
Enno Spillner, Chief Financial Officer
Kempen's 17
th
London Conference
Date
:
Tuesday, 24 November 2020
Venue
:
Virtual
Attendee
:
Dr Werner Lanthaler, Chief Executive Officer
Structured FINANCE Digital Week
Date
:
Wednesday, 25 November 2020
Venue
:
Virtual
Attendee
:
Enno Spillner, Chief Financial Officer
18
th
Berenberg European Conference
Date
:
Wednesday, 02 December 2020
,
Presentation: 02 December 2020, 4.00 pm (CET)
Venue:
Virtual
Attendee
:
Dr Werner Lanthaler, Chief Executive Officer
ABOUT EVOTEC SE
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 3,400 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases and women's health. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to
www.evotec.com
and follow us on Twitter
@Evotec
.
FORWARD-LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.
IR Contact Evotec SE:
Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775,
Media Contact Evotec SE:
Gabriele Hansen, SVP Head of Global Corporate Communications & Marketing, Phone: +49.(0)40.56081-255,
SOURCE:
Evotec AG via EQS Newswire
View source version on accesswire.com:
https://www.accesswire.com/614415/Evotec-to-Attend-Upcoming-Investor-Conferences
View comments
很赞哦!(9633)
相关文章
- Vishay Precision Group, Inc. to Host Earnings Call
- Ohio State tops Washington 28-23 in Meyer's Rose Bowl finale
- Jaguar Health to Host Investor Call January 7th at 8 a.m. Eastern to Review 4Q'18 Performance
- Dungeons & Dragons makes a comeback: Is it possible to play a game of D&D in a day?
- U.S. CDC reports 1,827,425 coronavirus cases
- Wiseway Group Limited (ASX:WWG) Is Employing Capital Very Effectively
- BRIEF-Bright Real Estate's Unit Wins Land Auction For 293.2 Million Yuan In Yunnan Province
- Why Yangaroo Inc.’s (CVE:YOO) High P/E Ratio Isn’t Necessarily A Bad Thing
- Castlebar Capital Corp. Announces Termination of LOI Respecting Qualifying Transaction
- Does Cosmo Pharmaceuticals N.V.’s (VTX:COPN) CEO Salary Compare Well With Others?
热门文章
- Data Science Salon Launches Three Four-Day Verticalized Virtual Salons
- The 3 Best Stocks in the Dow Jones in 2018
- Gold Jumps on Safe-Haven Demand, Drop in Saudi Exports Boosts Crude, Weather Woes Weigh on Natural Gas
- Drill, China, drill: State majors step on the gas after Xi calls for energy security
站长推荐
Barry Manilow and Darryl Payne Settle Copyright Dispute
Oil & Gas - Pipeline MLP Outlook: Near-Term Prospects Bleak
For Auld Lang Syne
Nigeria's Kaduna refinery expected to resume by mid-April - NNPC
Green Dot: 3Q Earnings Snapshot
Toronto house prices, listings surge in April but sales dip
Geena Davis on gender equality in Hollywood: 'Nothing changed' after Thelma and Louise
Oil & Gas - Pipeline MLP Outlook: Near-Term Prospects Bleak
友情链接
- FIRST FIRM TO INVESTIGATE NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Carnival Corporation & Plc and Encourages Investors with Losses of $100,000 to Contact the Firm
- Analyzing Brooks Automation's Ex-Dividend Date
- EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Tops Revenue Estimates
- How to Rise Above an ACT, SAT Test Score Plateau
- A design trends forecaster calls the coronavirus “an amazing grace for the planet”
- Hydro66 Announces Additional Advance Under Convertible Loan
- Bitcoin Falls 11% In Bearish Trade
- Coronavirus fears spark 'panic buying' of toilet paper, water, hand sanitizer. Here's why we all need to calm down
- Berkshire Hathaway annual meeting 2020: 5 things to know
- JPMorgan (JPM) Plans for 20% Rise in 2020-end Trading Bonus